Heron Therapeutics Inc. (NASDAQ:HRTX) – Analysts at Leerink Swann cut their FY2016 earnings per share (EPS) estimates for shares of Heron Therapeutics in a research note issued on Thursday. Leerink Swann analyst J. Gerberry now expects that the brokerage will post earnings per share of ($4.06) for the year, down from their previous forecast of ($4.01). Leerink Swann currently has a “Buy” rating and a $34.00 target price on the stock. Leerink Swann also issued estimates for Heron Therapeutics’ Q4 2016 earnings at ($0.92) EPS, FY2017 earnings at ($2.31) EPS, FY2018 earnings at ($1.15) EPS, FY2019 earnings at $1.07 EPS and FY2020 earnings at $4.62 EPS.
Heron Therapeutics (NASDAQ:HRTX) last issued its quarterly earnings results on Monday, August 8th. The biotechnology company reported ($1.17) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.96) by $0.21.
Other equities research analysts have also issued reports about the company. Cowen and Company reissued a “buy” rating on shares of Heron Therapeutics in a research report on Saturday, July 9th. Cantor Fitzgerald reissued a “buy” rating and issued a $41.00 price target on shares of Heron Therapeutics in a research report on Wednesday, August 3rd. Zacks Investment Research raised Heron Therapeutics from a “sell” rating to a “hold” rating in a research report on Tuesday. Brean Capital reissued a “buy” rating and issued a $55.00 price target on shares of Heron Therapeutics in a research report on Saturday, August 13th. Finally, Jefferies Group reissued a “buy” rating and issued a $46.00 price target on shares of Heron Therapeutics in a research report on Wednesday, July 27th. One analyst has rated the stock with a hold rating and eight have issued a buy rating to the stock. The company has an average rating of “Buy” and a consensus target price of $42.29.
Shares of Heron Therapeutics (NASDAQ:HRTX) opened at 16.29 on Monday. The firm has a 50-day moving average of $18.38 and a 200-day moving average of $18.91. Heron Therapeutics has a one year low of $15.13 and a one year high of $31.32.
In related news, insider Robert Rosen sold 100,000 shares of Heron Therapeutics stock in a transaction dated Wednesday, August 10th. The stock was sold at an average price of $23.30, for a total value of $2,330,000.00. Following the completion of the sale, the insider now owns 102,640 shares of the company’s stock, valued at approximately $2,391,512. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. 20.31% of the stock is owned by corporate insiders.
A number of large investors have recently made changes to their positions in HRTX. Brown Advisory Inc. raised its stake in shares of Heron Therapeutics by 3.9% in the second quarter. Brown Advisory Inc. now owns 307,827 shares of the biotechnology company’s stock valued at $5,557,000 after buying an additional 11,471 shares during the period. Nationwide Fund Advisors raised its stake in shares of Heron Therapeutics by 10.2% in the second quarter. Nationwide Fund Advisors now owns 20,730 shares of the biotechnology company’s stock valued at $374,000 after buying an additional 1,920 shares during the period. State Board of Administration of Florida Retirement System raised its stake in shares of Heron Therapeutics by 8.3% in the second quarter. State Board of Administration of Florida Retirement System now owns 16,739 shares of the biotechnology company’s stock valued at $302,000 after buying an additional 1,283 shares during the period. DIAM Co. Ltd. raised its stake in shares of Heron Therapeutics by 7.7% in the second quarter. DIAM Co. Ltd. now owns 300,337 shares of the biotechnology company’s stock valued at $5,406,000 after buying an additional 21,473 shares during the period. Finally, Emerald Acquisition Ltd. purchased a new stake in shares of Heron Therapeutics during the second quarter valued at $451,000.
Heron Therapeutics Company Profile
Heron Therapeutics, Inc is a biotechnology company engaged in developing pharmaceutical products for patients suffering from cancer or pain. The Company’s product candidates include SUSTOL, HTX-019 and HTX-011. All of its product candidates utilize science and technology platforms, including its Biochronomer drug delivery technology.
Receive News & Ratings for Heron Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heron Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.